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Current clinical trials for patients with acute lymphoblastic
leukemia (ALL) depend upon the measurement of minimal
residual disease (MRD) at early stages of therapy to determine
the risk of relapse for each patient who is being used for
treatment stratiﬁcation.
1 PCR-based MRD tests are usually
designed to detect the speciﬁc rearrangements of immunoglo-
bulin and T-cell receptor (Ig/TCR) genes found in the leukemic
clone. We now present evidence supporting the hypothesis that
the most common deletion in the IKZF1 gene in ALL also provides
the basis for highly sensitive MRD tests that give MRD results in
close agreement with Ig/TCR MRD markers.
Mullighan et al.
2 reported that DNA copy-number alterations
(CNAs) in the IKZF1 gene, which codes for the lymphoid
transcription factor IKAROS, were very common in leukemic DNA
from Philadelphia chromosome (Ph)-positive ALL patients (83%).
CNAs were not detected in the IKZF1 gene at diagnosis in 23
patients with chronic myeloid leukemia but IKZF1 CNAs were
found after blast crisis (that is, conversion to acute form of
leukemia) in 4 out of 15 patients including 3 out of 4 patients with
lymphoid blast crisis.
2 A subsequent study showed CNAs in IKZF1
in 29% of high risk, Ph-negative ALLs.
3 One quarter to one third of
patients with IKZF1 alterations had a deletion of exons 4--7;
corresponding to loss of coding exons 3--6 and resulting in
the expression of a dominant-negative IKAROS isoform, IK6.
2
The deletion breakpoints for these IKZF1D3--6 alterations are
usually located within a few nucleotides, and have characteristic
N regions comparable to Ig/TCR gene rearrangements.
These ﬁndings suggested the feasibility of designing MRD
assays based on real-time quantitative (RQ) PCR in the same way
as Ig/TCR-based MRD tests. One possibility was the use of two
primers and a probe, with one primer speciﬁc for the unique
N regions at the breakpoint fusion site. Another possibility was
the use of a generic IKZF1D3--6 RQ-PCR assay based on one probe
and two primers that all bind to germline sequences and create
a PCR product that bridges the breakpoint. Given the assumption
that these IKZF1 rearrangements are absent or rare in normal
lymphocytes, such a germline assay might be speciﬁc for
leukemia. These approaches were assessed by comparison with
standard Ig/TCR-based MRD tests.
Patients carrying the IKZF1D3--6 deletion were identiﬁed by
two alternate methods. PCR analysis of diagnosis leukemic
samples with published IKZF1 primers
2 was used to identify 28
patients (6%) in a set of 458 patients enrolled on the Australian
and New Zealand Children’s Haematology Oncology Group
(ANZCHOG) Study 8 clinical trial. For patients enrolled on the
Dutch Clinical Oncology Group (DCOG) ALL9 trial, an IKZF1
focused multiplex ligation-dependent probe ampliﬁcation test
was used and revealed a range of CNAs involving the IKZF1 gene
in 15/34 (44%) of relapse cases and 18/131 (14%) of unselected
patients.
4,5 Some of the patients with the IKZF1 D3--6 deletion
were used in this study. This research was approved by the
institutional bioethics committees at University of New South
Wales and Erasmus Medical Centre with informed consent from
parents of children for the use of the samples for research.
The subsequent RQ-PCR analyses for MRD were performed using
different sets of primers and probes to detect the IKZF1 deletion,
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diluted in normal mononuclear cell DNA in 25ml volumes in 96-well
plates. The RQ-PCR of ANZCHOG patients was performed using set A
or set B on 500-ng DNA with KAPA Biosystems (Boston, MA, USA)
mastermix using a touchdown program (with extension temperature
dropping by 11C for 10 cycles from 711Ct o6 1 1C and then a further
45 cycles) on the Biorad (Hercules, CA, USA) IQ5 or CFX96 platform.
The RQ-PCR of DCOG patients was performed using set C on 600ng
DNA with Universal mastermix (Roche, Indianapolis, IN, USA) on an
Applied Biosystems (ABI, Foster City, CA, USA) StepOne plus cycler.
MRD tests using set A primers and probe were performed on 61
follow-up bone marrow samples from eight patients, set B on 57
samples from seven patients (four in common with set A) and set C
on 44 samples from seven patients. All MRD data were assessed
according to EuroMRD guidelines.
6
The set A primers and probe were designed to detect all 28
IKZF1 D3--6 rearrangements in ANZCHOG Study 8 patients
allowing for the most truncated intron 2 and intron 6 sequences,
and has a forward primer and a minor groove binding probe both
binding to intron 2 upstream of the breakpoint and a reverse
Figure 1. Primers and probes used for RQ-PCR analysis of IKZFD3--6 deletions. The gene coding for Ikaros has eight exons (gray boxes 0--7),
of which 1--7 are coding. The sequence between the two breakpoint arrows is deleted in IKZF1D3--6, and this gene alteration can be detected
by RQ-PCR using primer sets A, B or C (horizontal arrows, and F-IKZF1 and R-IKZF1 sequences) and probes (open boxes and T-IKZF1
sequences). For both sets A and C, the 50 primer and probe match sequences before the breakpoint in intron 2 and the 30 primer binds after
the breakpoint in intron 6. Set B used the same probe and 50 primer as set A in combination with a different allele-speciﬁc primer for each
patient which bridged the unique breakpoint sequence. Both probes were synthesized by Applied Biosystems, but with different chemical
structures: T-IKZF1-A/B has a minor groove binding capacity, and T-IKZF1-C is a TAMRA Taqman probe. The location of primer and probe
sequences shown in brackets are according to NT_033968.6.
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forward primer as set A, but was used in combination with an
allele-speciﬁc reverse primer (positioned over the breakpoint
fusion). Set C was used in the Dutch cohort and has primers and a
Taqman probe in similar positions as set A but all closer to the
breakpoint giving a shorter product. The random deletions and
insertions of bases at the breakpoint fusion cause variations in the
size of the PCR products between the patients, but the size for the
RQ-PCR product with no insertion or deletion is 171 base pairs for
set A and 109 base pairs for set C. Set C was therefore potentially a
more efﬁcient RQ-PCR assay than A, but it would not be suitable
for about 25% of patients with IKZF1 D3--6 rearrangements.
An overall comparison of MRD results obtained with the
IKZF1D3--6 marker tested on the same samples as earlier MRD
analyses using Ig/TCR markers is shown in Figure 2a. The close
concordance of results was conﬁrmed by the Spearman’s
coefﬁcient of rank correlation (rho) of 0.985 (0.979--0.989 95%
conﬁdence interval; Po0.0001). This scattergram also illustrates
the limits to MRD testing with less reliable results obtained for
MRD levels o10
 4 (1 in 10000 cells). The results are highly
correlated with a slope of the linear regression of the log10 MRD
values approximating 1 (0.98±0.13). The IKZF1 results were as
close to the Ig/TCR results as an earlier study in which we
examined reproducibility by repeating MRD tests for samples
using Ig/TCR markers.
7
To assess the three different primer/probe IKZF1 sets used to
measure MRD, Bland--Altman analyses
8 were performed for each
set, comparing the difference in MRD level for the IKZF1 marker
and Ig/TCR markers, regarded as the current gold standard
(Figures 2b--d). On the basis of this analysis, all three IKZF1 MRD
sets of reagents provided highly suitable MRD tests, generating
MRD results in close concordance with Ig/TCR MRD results tested
on the same samples. In each set, the average difference and
regression lines were not signiﬁcantly different from zero and
there was no real difference in standard deviations. Samples from
four of the patients were tested using both Set A and Set B, and
the concordance of results was also high (data not shown).
The three IKZF1 MRD sets all showed high speciﬁcity with no or
very-low levels of background ampliﬁcation observed for control
mononuclear cell samples from individuals without leukemia,
which were included in every patient assay. Established EuroMRD
(ESG-MRD-ALL) guidelines were used to assess all MRD data
6 and
the assay slopes, quantitative ranges and sensitivities are shown in
the Supplementary Information for the paper. The slopes for set A
ampliﬁcation curves (3.40±0.16, mean±s.d.) were not higher
than set C MRD tests (3.55±1.3), suggesting that the longer
RQ-PCR product did not reduce the efﬁciency of the assay. With
a single exception, (quantitative range of 5 10
 4 for one set B
assay), all the IKZF1 MRD assays would meet current clinical trial
requirements with quantitative ranges and sensitivities between
10
 4 and 10
 5 corresponding to the detection of a single
leukemic cell in 10000 to 100000 normal cells.
Given the relatively small number of patients and the high level
of concordance of MRD results, it is not possible to identify one of
the methods as superior. All three IKZF1 sets have given highly
acceptable MRD results in comparison to regular Ig/TCR-based
MRD tests. Set A is applicable to more patients with the
IKZF1D3--6 deletion including those with slightly longer trunca-
Figure 2. Measurement of MRD using markers based on IKZF1 D3--6 deletions compared with Ig/TCR rearrangements. The RQ-PCR MRD
data were interpreted using EuroMRD guidelines
6 and the analyses use the log10MRD of the dilution of diagnosis sample giving the
same ampliﬁcation as each sample. (a) Scatterplot comparing overall MRD results on 164 bone marrow samples from 16 patients tested
using both methods. (b--d) Bland--Altman analysis for the three different IKZF1 MRD tests displayed as the difference in results for the
IKZF1 and Ig/TCR markers against the Ig/TCR gold standard.
7 All negative MRD results were coded as log10 MRD of  8 and non-quantitative
results as  6 as standardized by the EuroMRD. Figure 2b shows data for IKZF1 set B obtained with patient/allele assays each designed
so that one primer binds to the speciﬁc breakpoint sequence, Figure 2c shows data for Set A germline primer/probe combination
(with same probe as Set B) and Figure 2d shows Set C data for a different germline primer/probe set.
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requiring DNA sequencing or speciﬁc custom-made primers.
Two DNA MRD markers with high sensitivity (at least 10
 4) are
generally required in MRD intervention clinical trials,
1,9 and in a
large cohort of 2854 pediatric precursor B ALL patients, 20% of
patients had only one sensitive marker and 8% had none.
9 Four of
the 16 cases evaluated in this study had only one sensitive Ig/TCR
marker so that availability of IKZF1-based MRD testing would have
been useful for their risk stratiﬁcation. Using routine PCR,
IKZF1D3--6 rearrangements were identiﬁed in 6% of ALL patients
in the ANZCHOG cohort in this study, so inclusion of this marker in
standard screening for MRD targets would be an easy way to
provide more patients with two sensitive markers.
The concept of using disease-related markers for MRD testing has
been already established for fusion transcripts such as BCR-ABL and
for gene rearrangements such as for SIL-TAL1 in T-ALL and for MLL
rearrangements in infant ALLs.
10 Kuiper et al.
4 in an analysis of
paired diagnosis and relapse samples from 34 patients found IKZF1
deletions and nonsense mutations in 14 (41%) patients at diagnosis
and showed that all were conserved at relapse, in contrast to other
recurrent genetic lesions found at diagnosis such as PAX5, CDKN2A
and EBF1. It is therefore likely that this IKZF1 marker will be at least
as stable as Ig/TCR rearrangements, although this will need to be
conﬁrmed in more extensive studies.
In summary, we have assessed three ways to measure MRD
levels by RQ-PCR for the most common deletion of the IKZF1 gene
found in ALL and demonstrated that all three methods provided
robust and sensitive MRD assays for patients with this arrange-
ment. The two primer and probe sets based on germline
sequences could be used within a few days of diagnosis to
provide quantitative measures of very-early responses to therapy.
We expect that IKZF1 gene deletions (IKZF1D3--6 and probably
others) will provide a useful addition to the repertoire of MRD
markers currently available for monitoring MRD in ALL.
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Prognostic factors for acute myeloid leukemia patients with
t(6;9)(p23;q34) who underwent an allogeneic hematopoietic stem
cell transplant
Leukemia (2012) 26, 1416--1419; doi:10.1038/leu.2011.350;
published online 9 December 2011
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is
often selected as a curative treatment strategy for acute myeloid
leukemia (AML). In particular, AML patients with poor cytogenetics
at diagnosis are considered for allo-HSCT as the ﬁrst-line
therapy.
1- -3 Recently, we have reported that AML with the
t(6;9)(p23;q34) abnormality, which predicts a very poor prognosis
in patients treated with chemotherapy,
4 is associated with an
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